In:
Clinical and Vaccine Immunology, American Society for Microbiology, Vol. 18, No. 10 ( 2011-10), p. 1600-1607
Abstract:
The objective of the present study was to compare the effects of the modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine (Ingelvac PRRS MLV; Boehringer Ingelheim Animal Health, St. Joseph, MO) on European and North American PRRSV shedding in the semen of experimentally infected boars. The boars were randomly divided into six groups. Vaccinated boars shed the North American PRRSV at the rate of 10 0.1 to 10 1.0 viral genome copies per ml and 3.63 to 10 1.1 50% tissue culture infective doses (TCID 50 )/ml, respectively, in semen, whereas nonvaccinated boars shed the North American PRRSV at the rate of 10 0.2 to 10 4.7 viral genome copies per ml and 1.14 to 10 3.07 TCID 50 /ml, respectively, in semen. Vaccinated boars shed the European PRRSV at the rate of 10 0.1 to 10 4.57 viral genome copies per ml and 1.66 to 10 3.10 TCID 50 /ml, respectively, in semen, whereas nonvaccinated boars shed the European PRRSV at the rate of 10 0.3 to 10 5.14 viral genome copies per ml and 1.69 to 10 3.17 TCID 50 /ml, respectively, in semen. The number of genomic copies of the European PRRSV in semen samples was not significantly different between vaccinated and nonvaccinated challenged European PRRSV boars. The present study demonstrated that boar vaccination using commercial modified live PRRSV vaccine was able to decrease subsequent shedding of North American PRRSV in semen after challenge but was unable to decrease shedding of European PRRSV in semen after challenge.
Type of Medium:
Online Resource
ISSN:
1556-6811
,
1556-679X
DOI:
10.1128/CVI.05213-11
Language:
English
Publisher:
American Society for Microbiology
Publication Date:
2011
detail.hit.zdb_id:
1496863-0
Permalink